# This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

> **NCT07028853** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 1000 (estimated)

## Conditions studied

- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Hormone Sensitive Prostate Cancer
- Prostate Cancer
- Cancer of the Prostate

## Interventions

- **DRUG:** Mevrometostat
- **DRUG:** Placebo
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT07028853
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-28
- **Primary completion:** 2028-09-12
- **Final completion:** 2034-12-08
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028853, "This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07028853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*